Total Payments
$768.23
2023 Payments
$78.73
Companies
14
Transactions
41
Medicare Patients
1,467
Medicare Billing
$208,682
Payment Breakdown by Category
Food & Beverage$685.54 (89.2%)
Education$82.69 (10.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $685.54 | 39 | 89.2% |
| Education | $82.69 | 2 | 10.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $181.61 | 11 | $0 (2023) |
| Astellas Pharma US Inc | $114.24 | 3 | $0 (2019) |
| TETRAPHASE PHARMACEUTICALS, INC. | $109.39 | 7 | $0 (2020) |
| Philips Electronics North America Corporation | $101.91 | 5 | $0 (2019) |
| ViiV Healthcare Company | $60.32 | 3 | $0 (2019) |
| Gilead Sciences, Inc. | $38.70 | 2 | $0 (2020) |
| Janssen Biotech, Inc. | $37.14 | 2 | $0 (2023) |
| ABBVIE INC. | $26.14 | 2 | $0 (2023) |
| Melinta Therapeutics, Inc. | $23.02 | 1 | $0 (2019) |
| Paratek Pharmaceuticals, Inc. | $17.78 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $78.73 | 4 | Janssen Biotech, Inc. ($37.14) |
| 2021 | $13.20 | 1 | AbbVie Inc. ($13.20) |
| 2020 | $111.53 | 7 | TETRAPHASE PHARMACEUTICALS, INC. ($32.75) |
| 2019 | $513.76 | 26 | Astellas Pharma US Inc ($114.24) |
| 2018 | $51.01 | 3 | Merck Sharp & Dohme Corporation ($33.19) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/06/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $12.94 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/08/2023 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 03/30/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $28.65 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/11/2023 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 06/10/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/25/2020 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/11/2020 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: ANTIBIOTIC | ||||||
| 02/05/2020 | TETRAPHASE PHARMACEUTICALS, INC. | XERAVA (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 02/04/2020 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.19 | General |
| 01/28/2020 | Cumberland Pharmaceuticals, Inc. | Vibativ (Drug) | Food and Beverage | In-kind items and services | $11.44 | General |
| Category: Infections and Infectious Diseases | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), PIFELTRO, DIFICID | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/09/2020 | TETRAPHASE PHARMACEUTICALS, INC. | XERAVA (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 12/17/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/10/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 11/19/2019 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA, SIVEXTRO | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/19/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2019 | Astellas Pharma US Inc | CRESEMBA (Drug), AMBISOME, MYCAMINE | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/15/2019 | ADVANCED RESPIRATORY, INC | The Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Airway Clearance Device | ||||||
| 10/08/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 09/26/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 09/18/2019 | Philips Electronics North America Corporation | inCourage (Device) | Food and Beverage | Cash or cash equivalent | $19.13 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 08/27/2019 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/13/2019 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: HIV | ||||||
| 08/12/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 244 | 423 | $74,619 | $30,482 |
| 2022 | 6 | 374 | 704 | $116,279 | $47,950 |
| 2021 | 6 | 456 | 918 | $155,410 | $70,083 |
| 2020 | 7 | 393 | 795 | $132,782 | $60,167 |
Total Patients
1,467
Total Services
2,840
Medicare Billing
$208,682
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 92 | 210 | $26,040 | $12,358 | 47.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 50 | 51 | $19,431 | $6,871 | 35.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 78 | $14,820 | $4,980 | 33.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 52 | $9,256 | $4,638 | 50.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 20 | $2,708 | $929.20 | 34.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $2,364 | $707.07 | 29.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 167 | 421 | $52,204 | $22,841 | 43.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 73 | 75 | $26,925 | $11,152 | 41.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 54 | 90 | $17,100 | $6,077 | 35.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 41 | 71 | $12,638 | $5,300 | 41.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $5,382 | $1,701 | 31.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 21 | 29 | $2,030 | $878.69 | 43.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 200 | 557 | $69,068 | $31,464 | 45.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 111 | 113 | $39,946 | $18,178 | 45.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 61 | 116 | $20,846 | $9,566 | 45.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 51 | 81 | $14,897 | $6,105 | 41.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 40 | $9,883 | $4,458 | 45.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 11 | 11 | $770.00 | $312.83 | 40.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 188 | 546 | $72,005 | $31,219 | 43.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 97 | 99 | $32,826 | $16,140 | 49.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 44 | 73 | $13,096 | $6,127 | 46.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 15 | 23 | $5,017 | $2,170 | 43.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 24 | 27 | $4,424 | $1,940 | 43.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 14 | 14 | $3,210 | $1,555 | 48.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 11 | 13 | $2,204 | $1,016 | 46.1% |
About Dr. Martha Mooney, MD
Dr. Martha Mooney, MD is a Infectious Disease healthcare provider based in Newport News, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902872203.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martha Mooney, MD has received a total of $768.23 in payments from pharmaceutical and medical device companies, with $78.73 received in 2023. These payments were reported across 41 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($685.54).
As a Medicare-enrolled provider, Mooney has provided services to 1,467 Medicare beneficiaries, totaling 2,840 services with total Medicare billing of $208,682. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine
- Location Newport News, VA
- Active Since 02/27/2006
- Last Updated 10/19/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1902872203
Products in Payments
- inCourage (Device) $101.91
- NOXAFIL (Drug) $78.25
- Xerava (Drug) $76.64
- DIFICID (Drug) $58.10
- CRESEMBA (Drug) $44.25
- DOVATO (Drug) $42.50
- AVYCAZ (Drug) $40.47
- SYMTUZA (Drug) $37.14
- XERAVA (Drug) $32.75
- Baxdela (Drug) $23.02
- JULUCA (Drug) $17.82
- NUZYRA (Drug) $17.78
- ISENTRESS (Drug) $17.77
- The Vest System Model 105 Home Care (Device) $16.42
- Arikayce (Drug) $15.79
- CUBICIN RF (Drug) $14.79
- ZERBAXA (Drug) $12.70
- Vibativ (Drug) $11.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Newport News
Andrea Gonzalez, M.d, M.D
Infectious Disease — Payments: $19,320
Infectious Disease $19,320
Jeffrey Harris, M.d, M.D
Infectious Disease — Payments: $1,136
Infectious Disease $1,136
Rohit Kalia, Md, MD
Infectious Disease — Payments: $301.86
Infectious Disease $301.86
Dr. Prakash Kafle, M.d, M.D
Infectious Disease — Payments: $274.09
Infectious Disease $274.09
Dr. Sharon Hopson, M.d, M.D
Infectious Disease — Payments: $108.19
Infectious Disease $108.19